Home › Compare › MYTEF vs ABBV
MYTEF yields 4.22% · ABBV yields 3.06%● Live data
📍 MYTEF pulled ahead of the other in Year 2
Combined, MYTEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MYTEF + ABBV for your $10,000?
Telekom Malaysia Berhad engages in the establishment, maintenance, and provision of telecommunications and related services in Malaysia and internationally. It operates through unifi, TM ONE, TM WHOLESALE, and Shared Services/Others segments. The company offers a suite of communication services and solutions in fixed telephony and broadband, mobility, content, Wi-Fi, information and communications technology (ICT), cloud, data center, and smart services. It also provides network connectivity and bandwidth; project management; managed network, and value-added telecommunication and information technology services; cloud consumption; and transmission of voice and data services, as well as develops and sells software products. In addition, the company engages in the provision of research and development activities in the areas of communications, hi-tech applications, and products and services in related business; management of customer care services; trading of customer premises telecommunication equipment; property development activities; and content and application development for internet services. Further, it provides printed and online telephone directories; broadband network infrastructure facilities and services; and network system integration, network centric, integrated security management system, and fleet management services, as well as training and related services. Additionally, the company builds, provides, and manages smart buildings, which include smart tenant services for the building owners, operators, residents, and visitors; international telecommunications; ICT system security. It serves approximately 2.78 million fixed broadband customers. The company was founded in 1946 and is headquartered in Kuala Lumpur, Malaysia.
Full MYTEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.